JP2024537298A - 肺がんの治療用ｒｎａ - Google Patents

肺がんの治療用ｒｎａ Download PDF

Info

Publication number
JP2024537298A
JP2024537298A JP2024521854A JP2024521854A JP2024537298A JP 2024537298 A JP2024537298 A JP 2024537298A JP 2024521854 A JP2024521854 A JP 2024521854A JP 2024521854 A JP2024521854 A JP 2024521854A JP 2024537298 A JP2024537298 A JP 2024537298A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
rna
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537298A5 (https=
Inventor
ウグール・ザヒン
ダーヴィト・ヴェーバー
カリーナ・ヴァルター
ディアナ・バレア・ロルダン
ループレヒト・クーナー
メラニー・ハイン
マルティン・ズハン
ヴェレーナ・キスラー
レナ・マレーン・クランツ
Original Assignee
バイオンテック・エスイー
トロン－トランスラショナル・オンコロジー・アン・デア・ウニヴェルシテーツメディツィン・デア・ヨハネス・グーテンベルク－ウニヴェルシテート・マインツ・ゲマインニューツィゲ・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/078022 external-priority patent/WO2023061550A1/en
Application filed by バイオンテック・エスイー, トロン－トランスラショナル・オンコロジー・アン・デア・ウニヴェルシテーツメディツィン・デア・ヨハネス・グーテンベルク－ウニヴェルシテート・マインツ・ゲマインニューツィゲ・ゲーエムベーハー filed Critical バイオンテック・エスイー
Publication of JP2024537298A publication Critical patent/JP2024537298A/ja
Publication of JP2024537298A5 publication Critical patent/JP2024537298A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024521854A 2021-10-11 2022-10-10 肺がんの治療用ｒｎａ Pending JP2024537298A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2021/078022 2021-10-11
PCT/EP2021/078022 WO2023061550A1 (en) 2021-10-11 2021-10-11 Therapeutic rna for lung cancer
EPPCT/EP2022/050135 2022-01-05
EP2022050135 2022-01-05
PCT/EP2022/078084 WO2023061931A1 (en) 2021-10-11 2022-10-10 Therapeutic rna for lung cancer

Publications (2)

Publication Number Publication Date
JP2024537298A true JP2024537298A (ja) 2024-10-10
JP2024537298A5 JP2024537298A5 (https=) 2025-10-22

Family

ID=84286153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521854A Pending JP2024537298A (ja) 2021-10-11 2022-10-10 肺がんの治療用ｒｎａ

Country Status (11)

Country Link
US (1) US20240415946A1 (https=)
EP (1) EP4415747A1 (https=)
JP (1) JP2024537298A (https=)
KR (1) KR20240099175A (https=)
AR (1) AR127317A1 (https=)
AU (1) AU2022365280A1 (https=)
CA (1) CA3234915A1 (https=)
IL (1) IL312026A (https=)
MX (1) MX2024004421A (https=)
TW (1) TW202333803A (https=)
WO (1) WO2023061931A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025201659A1 (en) * 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001231204A1 (en) * 2000-01-27 2001-08-07 Sidney Kimmel Cancer Center Genetically engineered tumor cell vaccines
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US20180126003A1 (en) * 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
TW202134430A (zh) * 2019-12-03 2021-09-16 美商紐沃進公司 腫瘤細胞疫苗

Also Published As

Publication number Publication date
MX2024004421A (es) 2024-05-06
AR127317A1 (es) 2024-01-10
WO2023061931A1 (en) 2023-04-20
IL312026A (en) 2024-06-01
US20240415946A1 (en) 2024-12-19
TW202333803A (zh) 2023-09-01
EP4415747A1 (en) 2024-08-21
AU2022365280A1 (en) 2024-05-02
KR20240099175A (ko) 2024-06-28
CA3234915A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
JP6571822B2 (ja) 酵母−ｍｕｃ１免疫療法用組成物およびその使用
Weide et al. Plasmid DNA-and messenger RNA-based anti-cancer vaccination
CN112638404A (zh) 新抗原及其用途
JP7740988B2 (ja) 前立腺癌のための治療用ｒｎａ
AU2014298504A1 (en) Tumor antigens for determining cancer therapy
JP2025122023A (ja) 卵巣癌のための治療用ｒｎａ
WO2023006920A1 (en) Compositions and methods for treatment of melanoma
KR20200067862A (ko) 종양-관련된 항원 에피토프의 미생물 서열 변이체
JP2015520129A (ja) 多価乳がんワクチン
JP2023017853A (ja) 新規な癌抗原及び方法
US20250295746A1 (en) Therapeutic rna for lung cancer
JP2024537298A (ja) 肺がんの治療用ｒｎａ
CN118843474A (zh) 用于肺癌的治疗性rna
HK40115742A (zh) 用於肺癌的治疗性rna
WO2023061550A1 (en) Therapeutic rna for lung cancer
US20260021184A1 (en) Cancer Antigens and Methods
US20260116941A1 (en) Modified mammalian vesicles and compositions and methods related thereto
RU2832172C2 (ru) Терапевтическая рнк для рака яичника
CN118434442A (zh) 用于肺癌的治疗性rna
WO2025224446A1 (en) Novel cancer antigens and methods
HK40064177A (en) Therapeutic rna for ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251010